Wednesday, March 11, 2026 6:02:13 PM
To the "missing-brains" crowd (Exwannabe et al.):
Your argument that I should "sell at $1.78 and buy back at $0.24" is the hallmark of a paper-trader who doesn't understand Market Structure 101. Here is why your "rinse and repeat" logic is a mechanical impossibility:
The "Normal - Closed" Gate: You are screaming at a locked door. The LSE 0K95 instrument is currently in a "Normal - Closed" status (verified March 11, 2026). You cannot sell into a market that is not yet accepting retail flow. The £1.31 ($1.78) is the Sovereign Floor—it is a price barrier for the settlement, not a liquidity pool for your convenience.
The Tally Doesn't Lie: I'm not looking at a vague dollar amount; I’m looking at the 165,000,000 share tally currently accounted for in the Sovereign Vault. That is physical supply removed from the tradable float. You can't "arbitrage" shares that are locked in a vault pending institutional settlement.
The Brain-Gap on Liquidity: You claim it's "nuts" that anyone would buy at $1.78 when it's $0.24 on the OTC. It’s only nuts if you think institutional block trades work like a retail app. Market Makers are desperate for you to "sell at $0.24" because they know they cannot cover the gap once the LSE gate actually opens and that 165M block is reconciled.
The "Shill" Playbook: You’ve been bashing this for more than the 8 years I've held this stock. If the stock is "worthless," why are you still here? If the $1.78 doesn't exist, why is it on the official LSE tape?
Bottom line: I focus on the tape and the 165,000,000 share tally, you focus on the narrative. I’ll stick with the data.
Your argument that I should "sell at $1.78 and buy back at $0.24" is the hallmark of a paper-trader who doesn't understand Market Structure 101. Here is why your "rinse and repeat" logic is a mechanical impossibility:
The "Normal - Closed" Gate: You are screaming at a locked door. The LSE 0K95 instrument is currently in a "Normal - Closed" status (verified March 11, 2026). You cannot sell into a market that is not yet accepting retail flow. The £1.31 ($1.78) is the Sovereign Floor—it is a price barrier for the settlement, not a liquidity pool for your convenience.
The Tally Doesn't Lie: I'm not looking at a vague dollar amount; I’m looking at the 165,000,000 share tally currently accounted for in the Sovereign Vault. That is physical supply removed from the tradable float. You can't "arbitrage" shares that are locked in a vault pending institutional settlement.
The Brain-Gap on Liquidity: You claim it's "nuts" that anyone would buy at $1.78 when it's $0.24 on the OTC. It’s only nuts if you think institutional block trades work like a retail app. Market Makers are desperate for you to "sell at $0.24" because they know they cannot cover the gap once the LSE gate actually opens and that 165M block is reconciled.
The "Shill" Playbook: You’ve been bashing this for more than the 8 years I've held this stock. If the stock is "worthless," why are you still here? If the $1.78 doesn't exist, why is it on the official LSE tape?
Bottom line: I focus on the tape and the 165,000,000 share tally, you focus on the narrative. I’ll stick with the data.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
